William Blair Downgrades Adamas Pharmaceuticals (ADMS) to Market Perform, Following Acquisition
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Price: $8.22 --0%
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 8 | New: 6
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 8 | New: 6
Join SI Premium – FREE
William Blair analyst Tim Lugo downgraded Adamas Pharmaceuticals (NASDAQ: ADMS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.
Shares of Adamas Pharmaceuticals closed at $4.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades On Holding AG (ONON) to Market Perform
- Berenberg Downgrades Novo Nordisk (NVO) to Hold
- China Renaissance Downgrades Tencent Music Entertainment Group (TME) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
William BlairSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
